Ketanserin, a 5-HT2 antagonist, directly inhibits the ATP-sensitive potassium channel in mouse ventricular myocytes

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 1, 2006, Pages 96-102

  Ju, Jeong Min ^a   Hwang, Jae Ha ^a   Piao, Ling Hua ^a   Park, Hyung Wook ^a   Park, Jong Seong ^a   Shin, Dong Ho ^a   Cho, Jeong Gwan ^a   Kim, Kyung Keun ^a   Kim, Jae Ha ^a  

^a Chonnam National University   (South Korea)

Author keywords

Cardiomyocyte; Ischemia; KATP channel; Ketanserin

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; GLIBENCLAMIDE; KETANSERIN; PINACIDIL; PRAZOSIN; SEROTONIN; SEROTONIN 2 ANTAGONIST; ALPHA 1 ADRENERGIC RECEPTOR; ANTIARRHYTHMIC AGENT; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; SEROTONIN 2 RECEPTOR; SEROTONIN ANTAGONIST;

ANIMAL CELL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CELL ADHESION; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE; MOUSE; NONHUMAN; PATCH CLAMP; PIPETTE; PRIORITY JOURNAL; VOLTAGE CLAMP; WHOLE CELL; ANIMAL; CELL MEMBRANE POTENTIAL; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PHYSIOLOGY;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; KETANSERIN; MEMBRANE POTENTIALS; MICE; MICE, INBRED ICR; MYOCYTES, CARDIAC; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, SEROTONIN, 5-HT2; SEROTONIN ANTAGONISTS;

EID: 33646709914     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000196238.51018.e9     Document Type: Article

References (32)

1. Brogden RN, Sorkin EM. Ketanserin: a review of its pharmacodynamic and pharmacokinetic properties; and therapeutic potential in hypertension and peripheral vascular disease. Drug. 1990;40:903-949.
2. Frishman WH, Huberfeld S, Okin S, et al. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol. 1995;35:541-572.
3. Kamiya K, Venkatesh N, Singh BN. Acute and chronic effects of ketanserin on the electrophysiologic properties of isolated rabbit ventricular myocardium: particular reference to repolarization. Am Heart J. 1988;115:1222-1228.
4. Zaza A, Malfatto G, Rosen MR. Electrophysiologic effects of ketanserin on canine Purkinje fibers, ventricular myocardium and the intact heart. J Pharmacol Exp Ther. 1989;250:397-405.
5. Saman S, Thandroyen F, Opie LH. Serotonin and the heart. Effects of ketanserin on myocardial function, heart rate, and arrhythmias. J Cardiovasc Pharmacol. 1985;7(Suppl 7):S70-S75.
6. Arfiero S, Ometto R, Vincenzi M. Prolongation of the QT interval and torsades de pointes caused by ketanserin. G Ital Cardiol. 1990;20:869-872.
7. Aldariz AE, Romero H, Baroni M, et al. QT prolongation and torsades de pointes ventricular tachycardia produced by ketanserin. PACE. 1986;9:836-841.
8. Zhang ZH, Boutjdir M, EI-Sherif N. Ketanserin inhibits depolarization-activated outward potassium current in rat ventricular myocytes. Circ Res. 1994;75:711-721.
9. Le Grand B, Marty A, Colpaert FC, et al. Ketanserin inhibits the transient outward current in rabbit ventricular myocytes. J Cardiovasc Pharmacol. 1995;25:341-344.
10. Le Grand B, Talmant JM, Rieu JP, et al. Investigation of the mechanism by which ketanserin prolongs the duration of the cardiac action potential. J Cardiovasc Pharmacol. 1995;26:803-809.
11. kr) by ketanserin in guinea pig ventricular myocytes. Circulation. 1992;86(Suppl I):I-694[abstract].
12. + channels in cardiac muscle. Nature. 1983;305:147-148.
13. Trube G, Hescheler J. Inward-rectifying channels in isolated patches of the heart cell membrane: ATP-dependence and comparison with cell-attached patches. Pflugers Arch. 1984;401:178-184.
14. Lynch JH, Sanguinetti MC, Kimura S, et al. Therapeutic potential of modulating potassium currents in the diseased myocardium. FASEB J. 1992;6:2952-2960.
15. Nichols CG, Lederer WJ. Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am J Physiol. 1991;261:H1675-H1683.
16. + loss in hypoxic and ischemic mammalian ventricle. J Physiol. 1992;447:649-673.
17. + channel blockers on the action potential shortening in hypoxic and ischemic myocardium. Br J Pharmacol. 1991;103:1019-1026.
18. + channel activators in cardiac electrophysiology and arrhythmias. Circulation. 1992;85:1627-1629.
19. 2) receptor antagonists in ischemic rat hearts. J Cardiovasc Pharmacol. 1993;22:664-672.
20. + channel activity in cardiac myocytes. Chon Med J. 2002;38:135-145.
21. Hamill OP, Marty A, Neher E, et al. Improved patch clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391:85-100.
22. Spruce AE, Standen NB, Stanfield PR. Voltage-dependent ATP-sensitive potassium channels of skeletal muscle membrane. Nature. 1985;316:736-738.
23. Carlsson L, Abrahamsson C, Drews L, et al. Antiarrhythmic effects of potassium channel openers in rhythms abnormalities related to delayed repolarization. Circulation. 1992;85:1491-1500.
24. Takahashi N, Ito M, Saikawa T, et al. Nicorandil suppresses early afterdepolarization and ventricular arrhythmias induced by cesium chloride in rabbits in vivo. Cardiovasc Res. 1991;25:445-452.
25. Coronel R. Heterogeneity in extracellular potassium concentration during early myocardial ischemia and reperfusion: implications for arrhythmogenesis. Cardiovasc Res. 1994;28:770-777.
26. Grover GJ, Sleph PG, Dzwonczyk S. Pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat heart and anesthetized dogs. J Cardiovasc Pharmacol. 1990;16:853-864.
27. + loss and cardiac function in ischemic and reperfused mammalian ventricle. Circ Res. 1992;71:1324-1333.
28. Tosaki A, Engelman RM, Rousou J, et al. Aggravation of reperfusion arrhythmias by pinacidil, a potassium channel opener. Circulation. 1992;86(Suppl 1):1-4.
29. Coker SJ, Ellis AM. Ketanserin and ritanserin can reduce reperfusioninduced but not ischemia-induced arrhythmias in anaesthetised rats. J Cardiovasc Pharmacol. 1987;10:479-484.
30. Kyriakides ZS, Sbarouni E, Nikolaou N, et al. Intracoronary ketanserin augments coronary collateral blood flow and decreases myocardial ischemia during balloon angioplasty. Cardiovasc Drugs Ther. 1999;13:415-422.
31. Kalyoncu NI, Ozyavuz R. Ketanserin inhibits digoxin-induced arrhythmias in the anaesthetized guinea-pig. Fundam Clin Pharmacol. 1999;13:646-649.
32. Reimann I, Frolich J. Mechanism of antihypertensive action of ketanserin in man. BMJ. 1983;287:381-383.